Andrew J. Roth

Articles

Questions Remain Regarding Combinations and Sequencing in pNETs

January 26th 2015

To gain insight into the unanswered questions surrounding the treatment of pNETs, OncLive interviewed Pamela L. Kunz, MD, Assistant Professor of Medicine/Oncology at Stanford University.

Enzalutamide Improves PFS Over Bicalutamide in mCRPC

January 23rd 2015

Enzalutamide increased progression-free survival (PFS) by nearly 10 months compared with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).

Expert Discusses Integration of PD-1 Inhibitors Into Clinical Practice

January 13th 2015

To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.

FDA Approves Olaparib for Advanced Ovarian Cancer

December 19th 2014

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

FDA Approves Ramucirumab for NSCLC

December 12th 2014

The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumor has progressed during or following treatment with platinum-based chemotherapy.

Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL

December 8th 2014

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.

Pembrolizumab Elicits Responses in Classical Hodgkin Lymphoma

December 7th 2014

Treatment with the PD-1 inhibitor pembrolizumab generated responses in 66% of patients with heavily pretreated classical Hodgkin lymphoma.

Three Experts Discuss the Use of Cetuximab in Head and Neck Cancers

November 30th 2014

Cetuximab is the only FDA-approved EGFR inhibitor for the treatment of squamous cell carcinoma of the head and neck.

FDA Grants Orphan Drug Designation to BGB324 for AML

November 24th 2014

The FDA has granted an orphan drug designation to the novel AXL inhibitor BGB324 (R428) for the treatment of patients with acute myeloid leukemia (AML).

Juno Files for IPO as CAR Therapies Continue to Advance

November 19th 2014

Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.

Integrated Care Model Emerges for Oncologic Emergencies

October 29th 2014

The treatment of cancer is complex, and what might seem like a relatively minor medical issue at first can quickly escalate into an emergency.

Blood Cancer-Related Mutations Commonly Found in Older Individuals

October 28th 2014

Mutations known to be involved in hematologic malignancies were found in the blood cells of 2%-3% of individuals over age 40 and 5%-6% of those over age 70.

European Commission Approves Ibrutinib for MCL, CLL

October 21st 2014

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

CAR Therapy Demonstrates Promise in ALL

October 17th 2014

The investigational chimeric antigen receptor (CAR) therapy CTL019 demonstrated promising activity in 2 pilot trials, eliciting complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL).

FDA Expands Approval of Lymphoseek to Breast Cancer and Melanoma

October 15th 2014

The FDA has expanded the approval of Lymphoseek (technetium Tc 99m tilmanocept) injection to include lymphatic mapping in solid tumors and sentinel lymph node (SLN) detection for breast cancer and melanoma

NCI Awards $1.4 Million Grant to Develop Test for B-Cell NHLs

October 14th 2014

Advanced Cell Diagnostics, Inc. (ACD) and Cleveland Clinic were jointly awarded a 2-year, $1.4 million grant from the National Cancer Institute (NCI) to develop and validate a diagnostic test to identify B-cell non-Hodgkin lymphomas (NHLs) from benign lymphoproliferative diseases.

Swain Provides Insight Into Updated CLEOPATRA Survival Findings

October 5th 2014

Pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median overall survival (OS) by 15.7 months over standard first-line therapy

Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents

October 4th 2014

Androgen receptor splice variant-7 (AR-V7) is a truncated form of the AR that does not have the ligand-binding domain. Detection of AR-V7 in circulating tumor cells (CTCs) can be used to predict resistance to AR-targeting agents, such as abiraterone or enzalutamide.

Infinity Inks Deals to Expand Research Into Duvelisib

September 23rd 2014

Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.

PREVAIL Trial Investigator Discusses Pre-Chemo Enzalutamide Indication

September 20th 2014

Last week, the FDA expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.